Cytochrome bc1 Catalytic Subunit Rip1 Modulates Antifungal Tolerance in Candida auris

Authors:

Abstract
Candida auris is an emerging fungal pathogen causing invasive infections in immunocompromised patients, with mortality rates reaching up to 60%. Pronounced drug resistance makes treatment failure common, and so does antifungal tolerance, a phenomenon enabling pathogen survival at supra-MIC concentrations without resistance mutations. Here, we uncover a mechanism of antifungal tolerance in C. auris engaging the mitochondrial cytochrome bc1 complex. Deletion of RIP1, a conserved catalytic complex subunit, does not significantly alter the susceptibility to caspofungin or voriconazole. However, rip1Δ mutants exhibit a marked reduction in antifungal tolerance across a wide range of supra-MIC concentrations. Transcriptomics reveals the dysregulation of multiple drug resistance and tolerance-related genes in the rip1Δ mutant, demonstrating a role for Rip1 in controlling antifungal susceptibility. Targeting cytochrome bc1 function with the fungal-specific inhibitor Inz-5 enhances antifungal action of both voriconazole and caspofungin. Additionally, ablation of RIP1 causes fitness defects, suggesting that cytochrome bc1 is a potential antifungal target against C. auris infections.
Funding Information
  • Austrian Science Fund (Candidomics - P-33425)
  • Austrian Science Fund (ChromFunVir - P-32582-B08)
  • Austrian Science Fund (FWF-SFB70-08)
  • Austrian Science Fund (TissueHome FWF-DOC32-B28)
  • European Society of Clinical Microbiology and Infectious Diseases (ESCMID Research Grant 2023)
  • ASEAN-European Academic University Network (Bernd Rode Award 2024)
  • ASEAN-European Academic University Network (Ernst Mach Grant)
  • National Institutes of Health (R01AI182977)

This publication has 42 references indexed in Scilit: